Evidence map›Paper›PMID 38911380›Full record

ArticleJournal of Cancer2024

Establishment of a SUMO pathway related gene signature for predicting prognosis, chemotherapy response and investigating the role of EGR2 in bladder cancer.

Han Xiao, Xiaoan Huang, Heyi Chen, Ying Zheng, Weihui Liu, Jiabi Chen, Ran Wei, Ming Lin, Qingshui Wang, Wei Zhuang

Abstract read
In one paragraph

Article in Journal of Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Han XiaoDepartment of Pathology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, China.
Xiaoan HuangDepartment of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian, China.
Heyi ChenDepartment of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian, China.
Ying ZhengDepartment of Obstetrics, Fuzhou Second Hospital, Fuzhou 350000, Fujian, China.
Weihui LiuDepartment of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian, China.
Jiabi ChenDepartment of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian, China.
Ran WeiSchool of Medical and Health Engineering, Changzhou University, Changzhou 213164, Jiangsu, China.
Ming LinDepartment of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian, China.
Qingshui WangThe Second Affiliated Hospital of Fujian University of Traditional Chinese Medical University Medicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Innovation and Transformation Center, Fujian University of Traditional Chinese Medicine, Fuzhou 350001, Fujian, China.
Wei ZhuangDepartment of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bladder cancerChemotherapy responseEGR2PrognosisSUMO

Identifiers

PMID38911380
PMCPMC11190772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.